Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
Wall Street's M&A Chatter From December 12: Fox-Disney, Repros Therapeutics-Allergan, Agrium-Macrofertil
Lightning Round: Jim Cramer Shares His Thoughts On Allergan, ETP, Cisco And More
Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism (Seeking Alpha)
Related VRX
32 Biggest Movers From Yesterday
32 Stocks Moving In Thursday's Mid-Day Session
' Stocks Move on Thursday (GuruFocus)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!

Partner Center